Mgodi NM, Kelly C, Gati B, et al. Factors Associated with Bone Mineral Density in Health African Women. Arch Osteoporos. 2015;10:206.

Mirembe BG, Kelly CW, Mgodi N, et al. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):287-94.

View » MTN 003B

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365(6): 493-505.

Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. (2014) Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90.

Fogel JM, Hudelson SE, Ou SS, et al. (2016) Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2016 July 1, 72(3): 304-9.

Eshleman SH, Hudelson SE, Redd AD, et al. (2017) Treatment as Prevention: Characterization of Partner Invections in the HIV Prevention Trials Network 082 Trial. J Acquir Immune Defic Syndr. 2017 Jan 1; 74(1): 112-116.

Eshleman SH, Wilson EA, Zhang XC, et al. (2017) Virologic outcomes in early antiretrovial treatment: HPTN 052. HIV Clin Trials. 2017 Apr 7: 1-10.

View » HPTN 052

Miller S, Eergel EF, El Ayadi AM, Gibbons L, Butrick EA, et al. (2013) Non-pneumatic anti-shock garment (NASG), a first-aid device to decrease maternal mortality from obstetric hemorrhage: a cluster randomized trial. PloS One; 8(10): e76477.

View » Non-Pneumatic Anti-Shock Garment (NASG), A First-Aid Device to Decrease Maternal Mortality from Obstetric Hemorrhage: A Cluster Randomized Trial

Fuscus SA, Cu-Uvin S, Tilahun Eshete A, Hughes MD, Bao Y, et al. (2013) Changes in HIV-1 Subtypes B and C Gential Tract RNA in Women and Men After Initiation of Antiretroviral Therapy. Clin Infec Dis 57(2): 290-297.

View » A5185s

Baeten JM, Planee-Phillips T, Brown ER, et. al. (2016) Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016 Dec 1;375(22):2121-2132

View » MTN 020 (ASPIRE)

Riddler SA, Husnik M, Gorbach PM, et al. (2016) Long-term follow-up of HIV seroconverters in microbicide trials - rationale, study design, and challenges in MTN 015. HIV Clin Trials. 2016 Sep;17 (5)204-11.

View » MTN 015

van der Straten A, Montgomery ET, Musara P, et al. (2015) Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS. 2015 Oct 23;29(16): 2161-71.

Musara P, Montgomery ET, Mgodi NM, et al. How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda, and Zimbabwe. AIDS Behav. 2017 Jan 21.

View » MTN 003D

Fowler MG, Qin M, Fiscus SA, Currier JS, et al (2016) Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med. 2016 Nov 3;375(18):1726-1737.

View » 1077BF – PROMISE

Bolton Moore C, Capparelli EV, Samson P, Bwakura-Dangarembizi M, et al. (2017) CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection. AIDS. 2017 May 15;31(8):1129-1136.

View » P1070

Gomani P, Matubu AT, Mujuru HA et al. (2015) Hematological and Biochemical Laboratory Reference Intervals for Zimbabwean Adolescents. Clin. Lab; 2015; 61:101-111

View » Establishment of Laboratory Reference Values for Harare, Chitungwiza, and Mutoko

Montgomery ET, Woodsong C, Musara P, Cheng H, Chipato T, et al. (2010) An acceptability and safety study of the Duet cervical barrier and gel delivery system in Zimbabwe. J Int AIDS Soc; 13:30.

View » An Acceptability and Safety Study of the Duet® Cervical Barrier and Gel Delivery System in Zimbabwe

Fritz K, McFarland W, Wyrod R, Chasakara C, Makumbe K, et al. (2011) Evaluation of a peer network-based sexual risk reduction intervention for men in beer halls in Zimbabwe: results from a randomized controlled trial. AIDS Behav; 15(8): 1732-44.

View » Linking Alcohol Use with HIV Risk Behavior and HIV Prevalence Among Beer Hall Patrons in Harare, Zimbabwe

Minnis AM, Muchini A, Shiboski S, Mwale M, Morrision C, Chipato T, et al. (2007) Audio computer-assisted self-interviewing in reproductive health research: reliability assessment among women in Harare, Zimbabwe. Contraception; 75 (1): 59-65.

View » The Reliability of ACASI Data Collection in Zimbabwe

Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, et al. (2007) Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomized controlled trial. Lancet; 370(9583): 251-61.

View » Diaphragm and Lubricant Gel for Prevention of HIV Acquisition in Southern African Women: A Randomized, Controlled Trial (MIRA)

Chidzonga MM, Mwale M, Malvin K, Martin K, Greenspan JS, et al. (2008) Oral candidiasis as a marker of HIV disease progression among Zimbabwean women. J Acquir Immune Defic Syndr; 47(5): 579-84.

View » Oral Candidiasis Marker of HIV-Disease Progression Among Zimbabwean Women

Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, et al. (2007) Hormonal contraception and the risk of HIV acquisition. AIDS; 21(1): 85-95.

View » Hormonal Contraception and the Risk of HIV-1 Acquisition Among Young Women in Uganda and Zimbabwe

van der Straten A, Napierala S, Cheng H, Mauck C, Depineres T, et al. (2007) A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe. Contraception; 76(5): 389-99.

View » A Randomized, Controlled Safety Trial of the Diaphragm and Cellulose Sulfate Microbicide Gel in Sexually Active Women in Zimbabwe

Chirenje ZM, Chipato T, Kasule J, Rusakaniko S (1999). Visual inspection of the cervix as a primary means of cervical cancer screening: results of a pilot study. Cent Afr J Med; 45(2): 30-3.

View » Visual Inspection of the Cervix as a Primary Means of Cervical Cancer Screening: Results of a Pilot Study

Marrazzo JM, Ramjee G, Richardson BA, et al. (2015) Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015 Feb 5;372(6): 509-18.

van der Straten A, Brown ER, Marazzo JM, et al. (2016) Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc. 2016 Feb 4;19(1):20642.

Akello CA, Bunge KE, Nakabiito C, et al. (2017) Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial. J Womens Health (Larchmt). 2017 Feb 17.

Chirenje ZM, Gudenacker HM, Richardson B, et al. (2017) Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003). Sex Trams Dis. 2017 Mar;44(3):135-140.

View » MTN 003 (VOICE)

MacQueen KM, Namey E, Chilongozi DA, et al (2007) Community perspectives on care options for HIV prevention trial participants. AIDS Care. 2007 Apr; 19(4):554-60.

Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, et al. (2011) Safety and effectiveness of BufferGel and 0.5% PRO 2000 gel for prevention of HIV infection in women. AIDS; 25(7): 957-66.

Chirenje ZM, Masse BR, Maslankowski LA, et al. (2012) Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 Gel. J Int AIDS Soc. 2012 Aug 27; 15(2):17376.

Dezzutti CS, Richardson BA, Marrazzo JM, et al. (2012) Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis. 2012 Dec 15; 206(12): 1931-35.

Richardson BA, Kelly C, Ramjee G, et al. (2013) Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a complarison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr. 2013 May 1; 63(1): 120-5.

Gorbach PM, Kelly CW, Borgerding JA, et al. (2014) Effects of partnership change on microbicide gel adherence in a clinical trial (HPTN 035). AIDS Behav. 2014 May; 18(5): 855-61.

Guffey MB, Richardson B, Husnik M, et al (2014) HPTN 035 phase II/IIb randomised safety and effectiveness study of vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sex Transm Infec. 2014 Aug; 90(5): 363-9.

Balkus JE, Brown ER, Hillier Sl, et al. (2016) Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. Contraception. 2016 Jan;93(1):25-31.

View » HPTN/MTN 035

van De Wilgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, et al. (2001) Phase 1 trial of the microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr; 26(1): 21-7.

View » Phase I Trial of the Topical Microbicide BufferGel

Violari A, Lindsey JC, Hughes MD, Mujuro HA, Barlow-Mosha L, et al. (2012) Nevirapine versus rtonavir-boosted lopinavir for HIV-infected children. N Engl J Med; 366 (25): 2380-9.

Lindsey JC, Hughes MD, Violari A. et al (2014) Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J. 2014 Aug;33(8):846-54.

View » P1060

Coovadia HM, Brown ER, Fowler ER, Chipato T, Moodley D, et al. (2012) Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomized, double-blind, placebo-controlled trial. Lancet; 379 (9812): 221-8.


Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. (2008) Effect of acyclovir on HIV-1 acquisition on herpes simplex virus 2 seropositive women and men who have sex with men: a randomized, double-blind, placebo-controlled trial. Lancet 371(9630): 2109-19.

View » HPTN 039

Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, et al. (2003) Safety and trough concentrations of nevirapine phrophylaxis given daily, twice daily, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Synd; 34(5): 482-90.

View » HIVNET/HPTN 023

Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365(16): 1482-91.

View » A5221

Lockman S, Hugues MD, McIntyre J, et al. (2010) Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14;363(16):1499-509.

Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, et al. (2012) Nevirapine-versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLos Med 9(6): e1001236.

Porter KA, Cole SR, Eron JJ Jr, et al. HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study. Antimicrob Agents Chemother. 2012 Feb;56(2):995-1000.

Skinner-Adams TS, Butterworth AS, Porter KA, et al. (2012) The frequency of maleria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. (2012) PLoS One 2012;7(4):e34399.

View » A5208

Robertson K, Jiang H, Kumwenda J, Supparatpinyo K, Evans S, et al. (2012) Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study A5199, the International Neurological Study. Clin Infect Dis 55(6): 868-76.

View » A5199

Nielsen-Saines K, Komarow L, Cu-Uvin S, Jourdain G, Klingman KL, et al. (2012) Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics 219(6): e1525-32.

View » A5190/P1054

Kumwenda N, Hoffman I, Chirenje ZM, Kelly C, Coletti A, et al. (2006) HIV incidence among women of reproductive age in Malawi and Zimbabwe. Sex Transm Dis; 33(11): 646-51


Robertson K, Jiang H, Kumwenda J, Supparatpinyo K, Evans S, et al. (2012) Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study A5199, the International Neurological Study. Clin Infect Dis 55(6): 868-76.

View » A5199

Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, et al. (2012) Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings. PLoS Med 9(8): e1001290.

Safren SA, Biello KB, Smeaton L, et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG 5175/PEARLS trial. PLoS One. 2014 Aug 25;9(8):e104178.

Touzard Romo F, Smeaton LM, Campbell TB, et al. (2014) Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverser, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials. 2014 Nov-Dec;15(6):246-60.

Kantor R, Smeaton L, Vardhanabhuti S, et al. (2015) Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated with Virologic Failure: Results from the Multinational PEARLS A5175) Clinical Trial. Clin Ifec Dis. 2015 May 15;60(10):1541-9.

Singini I, Campbell TB, Smeaton LM, et al (2016) Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy. HIV Clin Trials. 2016 Jul 29: 1-8.

Celum C, Hong T, Cent A, et al. (2017) HSV-2 acquisition among HIV-1 infected adults treated with tenofovir as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study. J Infect Dis. 2017 Jan 30.

View » A5175

List of all current and completed research